AN2 Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AN2 Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($35.17M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($51.32M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($64.73M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($40.96M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($21.54M) | Mar 29, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.11M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($56.79M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($69.64M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($42.26M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($21.57M) | Mar 29, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.95M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $92.09M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $138.74M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $102.56M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $65.32M | Mar 29, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.89M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $10.24M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $14.04M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $7.19M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.41M | Mar 29, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.06M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $81.85M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $124.70M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $95.37M | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | ($47.41M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | ($20.32M) | Mar 29, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (10) | Mar 29, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (10) | Mar 29, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.94M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $21.35M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $15.65M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $27.22M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $12.10M | Mar 29, 2023 |